Psoriatic Disease
Amgen, J&J settle ustekinumab patent lawsuit in potential biosimilar market shake-up
Johnson & Johnson has settled its lawsuit with Amgen regarding the latter company’s Stelara biosimilar, clearing the way for a January 2025 release date in the United States, according to results of a federal court filing.
EULAR removes systemic glucocorticoid use from psoriatic arthritis recommendations
EULAR has removed the use of systemic glucocorticoids from its recommendations for the management of psoriatic arthritis, according to a presentation at the EULAR 2023 Congress.
IL-12/23, IL-23 inhibitors reduce risk for progression to inflammatory arthritis vs. TNFi
Patients with psoriasis treated with interleukin-12/23 or IL-23 inhibitors may be less likely to progress to inflammatory arthritis than those treated with TNF inhibitors, according to data published in The Lancet Rheumatology.
Izokibep demonstrates ‘marked improvements’ in psoriatic arthritis at 46 weeks
The interleukin-17 inhibitor izokibep has demonstrated positive safety and efficacy data at 46 weeks among patients with psoriatic arthritis, according to a press release from its manufacturer.
‘No evidence’ of increased short-term cancer risk for JAK inhibitors vs. TNF inhibitors
Clinical data found “no evidence” of a higher short-term cancer risk, except for non-melanoma skin cancer, in patients with rheumatoid arthritis or psoriatic arthritis starting Janus kinase inhibitors vs. TNF inhibitors, researchers wrote.
Female patients with psoriatic arthritis less likely to achieve therapy goals on bDMARDs
Female patients with psoriatic arthritis who receive biologic disease-modifying antirheumatic drugs are more likely to have more severe disease and less likely to reach low or minimal disease activity vs. male patients, according to data.
Apremilast shows promise as first oral treatment for genital psoriasis
NEW ORLEANS — Apremilast 30 mg significantly improved genital psoriasis severity and quality of life compared with placebo in the first trial to study an oral treatment for this indication, according to a presentation here.
Glucocorticoid use, male sex predict more severe COVID-19 in psoriatic disease, axial SpA
Glucocorticoid use, older age, male sex and comorbidity burden are among the predictors of more severe COVID-19 in patients with psoriasis, psoriatic arthritis or axial spondyloarthritis, according to data.
Mandatory switching policies increased etanercept, infliximab biosimilar use in Canada
Mandatory switching policies for biosimilars are “much more” effective in increasing adoption than focusing on new start strategies, according to a study of Canadian health spending data published in Arthritis Care & Research.
Women with psoriatic arthritis report worse outcomes, treatment response vs. men
There are key sex-specific differences in how psoriatic arthritis manifests in patients, with women reporting worse outcomes and treatment response compared with men, according to a review published in The Journal of Rheumatology.